

CITATION REPORT

List of articles citing

Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis

DOI: 10.1001/archpsyc.63.11.1217

Archives of General Psychiatry, 2006, 63, 1217-23.

Source: <https://exaly.com/paper-pdf/41113325/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
300	Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. 2008 , 178, 296-305		76
299	Onset of action of antidepressants. 2007 , 334, 911-2		21
298	Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. 2007 , 52, 553-62		44
297	Regulation of corticolimbic reactivity via the 5-HT1A autoreceptor in the pathophysiology and treatment of depression. 2007 , 2, 121-124		2
296	Rapid response predicts binge eating and weight loss in binge eating disorder: findings from a controlled trial of orlistat with guided self-help cognitive behavioral therapy. 2007 , 45, 2537-50		41
295	Limitations of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic target. 2007 , 17, 743-55		31
294	Tratamiento farmacológico de la depresión. 2007 , 9, 5469-5477		
293	Dentate gyrus neurogenesis and depression. 2007 , 163, 697-722		76
292	The effects of serotonin manipulations on emotional information processing and mood. 2007 , 103, 43-62		87
291	5-HT1A receptors on oxytocin neurons and premature ejaculation--a comment. 2007 , 4, 1518; author reply 1519		1
290	Rapid onset of true antidepressant action. 2007 , 9, 475-9		11
289	Acute and chronic effects of citalopram on 5-HT1A receptor-labeling by [18F]MPPF and -coupling to receptors-G proteins. 2009 , 63, 106-16		17
288	Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities. 2008 , 18, 6088-92		7
287	Major depression: emerging therapeutics. 2008 , 75, 204-25		37
286	The effects of reboxetine on emotional processing in healthy volunteers: an fMRI study. 2008 , 13, 1011-20		57
285	Major depressive disorder. 2008 , 358, 55-68		1254
284	The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder. 2008 , 24, 3105-15		27

283	Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. 2008 , 22, 343-96	341
282	[Antidepressants and their onset of action: a major clinical, methodological and pronostical issue]. 2008 , 34, 73-81	21
281	Pathological laughing and crying : epidemiology, pathophysiology and treatment. 2008 , 22, 531-45	79
280	Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. 2008 , 33, 406-17	250
279	Abnormal temporal difference reward-learning signals in major depression. 2008 , 131, 2084-93	282
278	Inflammation, glutamate, and glia in depression: a literature review. 2008 , 13, 501-10	232
277	Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder. 2008 , 20, 309-27	16
276	Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant Action: Systematic Review and Meta-analysis. 2008 , 2008, 195-197	
275	A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. 2008 , 23, 269-75	24
274	Smoking induces long-lasting effects through a monoamine-oxidase epigenetic regulation. 2009 , 4, e7959	102
273	Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis. 2009 , 23, 539-50	20
272	Effect of acute antidepressant administration on negative affective bias in depressed patients. 2009 , 166, 1178-84	330
271	Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. 2009 , 117 Suppl 1, S26-43	298
270	How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. 2009 , 24, 269-75	39
269	Early prediction of the effectiveness of antidepressants: inputs from an animal model. 2009 , 39, 256-61	3
268	[Subdiagnostic depression. Are there treatments with clinically relevant effects?]. 2009 , 80, 532-4, 536-9	10
267	Short-term antidepressant treatment modulates amygdala response to happy faces. 2009 , 206, 197-204	78
266	Effect of a single dose of citalopram on amygdala response to emotional faces. 2009 , 194, 535-40	185

265	Dietary tryptophan depletion according to body weight - a new treatment option in acute mania?. 2009 , 72, 47-8	15
264	The Maudsley Prescribing Guidelines. 2009 ,	110
263	Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. 2009 , 18, 1753-64	49
262	Neurocognitive mechanisms in depression: implications for treatment. 2009 , 32, 57-74	301
261	P.2.c.006 Analysis of longitudinal clinical scores in major depressive disorder trials: comparison of linear and non-linear mixed effect modelling. 2009 , 19, S406-S407	
260	P.2.c.007 Benefits of switching antidepressants following early nonresponse. 2009 , 19, S407	2
259	P.2.c.008 Serotonin transporter gene polymorphisms, personality and response to serotonergic and noradrenergic antidepressants. 2009 , 19, S407-S408	
258	Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. 2009 , 373, 746-58	1217
257	Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. 2009 , 12, 1009-20	54
256	Using functional neuroimaging to investigate the mechanisms of action of selective serotonin reuptake inhibitors (SSRIs). 2010 , 16, 1990-7	23
255	Onset of clinical effects and plasma concentration of fluvoxamine in Japanese patients. 2010 , 33, 1999-2002	6
254	Frontal electroencephalogram changes in early phase antidepressant treatment predict clinical response in major depressive disorder. 2010 , 5, 17-20	
253	A critical review of human endotoxin administration as an experimental paradigm of depression. 2010 , 34, 130-43	124
252	Zorgbehoefte cognitief niet beperkte bejaarden duurt betrekkelijk kort. 2010 , 53, 353-353	0
251	Rethinking depression and the actions of antidepressants: uncovering the links between the neural and behavioral elements. 2010 , 120, 16-23	27
250	History of suicide attempts among patients with depression in the GENDEP project. 2010 , 123, 131-7	16
249	Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trial. 2010 , 11, 21	24
248	An algorithm for the pharmacological treatment of depression. 2010 , 121, 180-9	18

247	The dapoxetine paradox. 2010 , 105, 1041-2	2
246	The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. 2010 , 3, 19-41	108
245	Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine. 2010 , 62, 198-206	20
244	Fluvoxamine versus other anti-depressive agents for depression. 2010 , CD006114	26
243	To what extent do neurobiological sleep-waking processes support psychoanalysis?. 2010 , 92, 233-90	3
242	The clinical significance of antidepressant treatment effects cannot be derived from placebo-verum response differences. 2010 , 24, 445-8	38
241	Trajectories of change in depression severity during treatment with antidepressants. 2010 , 40, 1367-77	90
240	Therapy-resistant depression. 2010 , 10, 77-86	34
239	The importance of early symptom relief in antidepressant treatment: focus on agomelatine. 2010 , 24, 27-30	14
238	Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression. 2010 , 24, 1143-52	13
237	Lack of effect of citalopram on magnetic resonance spectroscopy measures of glutamate and glutamine in frontal cortex of healthy volunteers. 2010 , 24, 1217-21	14
236	Future suicide attempt and responses to serotonergic challenge. 2010 , 35, 1063-72	39
235	Epigenetic modifications: significance in drug addiction and treatment. 2010 , 2, 183-6	3
234	Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. 2010 , 67, 439-45	226
233	Antidepressant response and the serotonin transporter gene-linked polymorphic region. 2010 , 68, 536-43	101
232	A genomewide association study of citalopram response in major depressive disorder-a psychometric approach. 2010 , 68, e25-7	17
231	SSRI's in de Nederlandse huisartsenpraktijk. 2010 , 53, 302-305	4
230	Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. 2010 , 34, 259-64	50

229	Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. 2010 , 34, 437-8; author reply 439-40	6
228	Potentials and current limitations of brain stimulation therapies to accelerate antidepressant response. 2010 , 34, 439-440	
227	Role of Central Serotonin in Impulsivity and Compulsivity: Comparative Studies in Experimental Animals and Humans. 2010 , 21, 415-427	16
226	Antidepressant medications reduce subcortical-cortical resting-state functional connectivity in healthy volunteers. 2011 , 57, 1317-23	155
225	Sertraline vs. ELectrical Current Therapy for Treating Depression Clinical Trial--SELECT TDCS: design, rationale and objectives. 2011 , 32, 90-8	51
224	Commentary on the Cochrane Review of acupuncture for depression. 2011 , 7, 193-7	1
223	Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. 2011 , 59, 896-905	54
222	Psychopharmacology: a house divided. 2011 , 35, 1-10	6
221	Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. 2011 , 35, 1983-9	36
220	Serum brain-derived neurotrophic factor and glucocorticoid receptor levels in lymphocytes as markers of antidepressant response in major depressive patients: a pilot study. 2011 , 189, 239-45	34
219	Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. <i>Archives of General Psychiatry</i> , 2011 , 68, 1227-37	88
218	Faster onset of antidepressant effects of citalopram compared with sertraline in drug-naïve first-episode major depressive disorder in a Chinese population: a 6-week double-blind, randomized comparative study. 2011 , 31, 577-81	8
217	The componential approach enhances the effectiveness of 2-week trials for new antidepressants. 2011 , 31, 253-4	2
216	Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder. 2011 , 27, 805-10	9
215	Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. 2011 , 31, 187-93	28
214	Predictors of fluoxetine remission for hospitalized patients with major depressive disorder. 2011 , 65, 510-7	6
213	Fluoxetine alleviates behavioral depression while decreasing acetylcholine release in the nucleus accumbens shell. 2011 , 36, 1729-37	27
212	Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. 2011 , 130, 171-9	43

211	Monitoring of circadian rhythms of heart rate, locomotor activity, and temperature for diagnosis and evaluation of response to treatment in an animal model of depression. 2011 , 43, 303-8	5
210	Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder. 2011 , 11, 16	20
209	Meta-analysis: fact or fiction? How to interpret meta-analyses. 2011 , 12, 188-200	38
208	Next Generation Antidepressants. Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders. Edited by C. E. Beyer and S. M. Stahl. (Pp. 150; £50.00; ISBN 9780521760584 hb.) Cambridge University Press: Cambridge. 2010.. 2011 , 41, 1109-1111	
207	Geriatric pharmacology. 2012 , 38-63	
206	The drugs don't work? antidepressants and the current and future pharmacological management of depression. 2012 , 2, 179-88	103
205	Are antidepressants useful in the treatment of minor depression: a critical update of the current literature. 2012 , 25, 1-6	12
204	Newer antidepressants for the treatment of depression in adults. 2012 , 344, d8300	9
203	Early versus conventional switching of antidepressant: a post-hoc analysis of clinical trial data for major depressive disorder with moderate to severe pain symptoms. 2012 , 13, 2711-5	1
202	Early switch strategy in patients with major depressive disorder. 2012 , 12, 1185-8	7
201	Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. 2012 , 42, 967-80	229
200	Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate. 2012 , 15, 1541-6	24
199	Surrogate markers of treatment outcome in major depressive disorder. 2012 , 15, 841-54	18
198	Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. 2012 , 57, 782-8	23
197	Citalopram versus other anti-depressive agents for depression. 2012 , CD006534	37
196	Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?. 2012 , 22, 137-42	14
195	Onset, time course and trajectories of improvement with antidepressants. 2012 , 22 Suppl 3, S492-8	52
194	The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data. 2012 , 27, 522-7	11

193	[Integral Care Guide for Early Detection and Diagnosis of Depressive Episodes and Recurrent Depressive Disorder in Adults. Integral Attention of Adults with a Diagnosis of Depressive Episodes and Recurrent Depressive Disorder: Part II: General Aspects of Treatment, Management of the Acute Phase, Continuation and Maintenance of Patients with a Depression Diagnosis]. 2012 , 41, 740-73	2
192	Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression. 2012 , 62, 264-9	52
191	Antidepressants. 2012 , 40, 681-683	
190	Duloxetine versus other anti-depressive agents for depression. 2012 , 10, CD006533	43
189	Psychiatric Aspects of Parkinson's Disease in Animal Models of Deep Brain Stimulation of the Subthalamic Nucleus. 2012 , 175-182	
188	Analysis of region-specific changes in gene expression upon treatment with citalopram and desipramine reveals temporal dynamics in response to antidepressant drugs at the transcriptome level. 2012 , 223, 281-97	12
187	Pharmacology and neuroimaging of antidepressant action. 2012 , 106, 643-55	
186	A combined in vivo neurochemical and electrophysiological analysis of the effect of high-frequency stimulation of the subthalamic nucleus on 5-HT transmission. 2012 , 233, 145-53	34
185	Can effects of antidepressants in patients with mild depression be considered as clinically significant?. 2012 , 138, 183-91	20
184	Early pain reduction can predict treatment response: results of integrated efficacy analyses of a once-daily gastroretentive formulation of gabapentin in patients with postherpetic neuralgia. 2012 , 13, 1059-66	7
183	Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. 2012 , 46, 64-71	62
182	Bringing back melancholia. 2012 , 14, 1-5	15
181	Monoamine oxidases in development. 2013 , 70, 599-630	47
180	Investigating the psychopharmacology of cognitive affective bias in rats using an affective tone discrimination task. 2013 , 226, 601-13	62
179	Antidepressants and mood stabilizers effects on histone deacetylase expression in C57BL/6 mice: Brain region specific changes. 2013 , 47, 1204-14	39
178	Percentage reduction of depression severity versus absolute severity after initial weeks of treatment to predict final response or remission. 2013 , 67, 265-72	6
177	A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression?. 2013 , 67, 304-17	111
176	Resting state functional connectivity and treatment response in late-life depression. 2013 , 214, 313-21	102

175	Bupropion pre-treatment of endotoxin-induced depressive symptoms. 2013 , 31, 197-204	33
174	P.4.011 Clinical features and drug-induced side effects in early versus late antidepressant responders. 2013 , 23, S76-S77	
173	Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D. 2013 , 23, 612-21	22
172	Clinical features and drug induced side effects in early versus late antidepressant responders. 2013 , 47, 1309-18	24
171	Paroxetine in the treatment of dysthymic disorder without co-morbidities: A double-blind, placebo-controlled, flexible-dose study. 2013 , 6, 157-61	6
170	'It's the way that you look at it'--a cognitive neuropsychological account of SSRI action in depression. 2013 , 368, 20120407	109
169	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. 2013 , 14, 334-85	346
168	Suicide-related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis. 2013 , 3, e003247	11
167	Peripheral biomarkers in animal models of major depressive disorder. 2013 , 35, 33-41	12
166	Suggested early onset of true action of antidepressant drugs may be artefactual: a heuristic study. 2013 , 28, 29-32	1
165	Early improvement and serum concentrations of citalopram to predict antidepressant drug response of patients with major depression. 2013 , 46, 261-6	15
164	The superiority of antidepressant medication to cognitive behavior therapy in melancholic depressed patients: a 12-week single-blind randomized study. 2013 , 128, 271-81	16
163	Optimizing the management of depression: primary care experience. 2014 , 220 Suppl 1, S45-57	27
162	Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials. 2014 , 30, 263-70	14
161	Bupropion versus other antidepressive agents for depression. 2014 ,	1
160	Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression. 2014 , 29, 86-92	20
159	Long-term effects of the treatment of depressive female inpatients in a naturalistic study: is early improvement a valid predictor of outcome?. 2014 , 2014, 780237	1
158	Current and emerging drug treatments for binge eating disorder. 2014 , 19, 99-142	35

157	Prescribing selective serotonin reuptake inhibitors in older age. 2014 , 77, 118-23	12
156	Predictive value of baseline resistance in early response to antidepressants. 2014 , 161, 127-35	3
155	Sertraline effects on cerebrospinal fluid monoamines and species-typical socioemotional behavior of female cynomolgus monkeys. 2014 , 231, 1409-16	22
154	Antidepressant-related sexual dysfunction - perspectives from neuroimaging. 2014 , 121, 138-45	35
153	Pharmacological Treatment of Anxiety Disorders. 2014 , 865-882	1
152	Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: The significance of early rapid response. 2015 , 83, 387-94	25
151	Pharmacological Management of Treatment-Resistant Unipolar Depression. 2015 , 2311-2330	1
150	References. 2015 , 225-246	
149	A role of Yueju in fast-onset antidepressant action on major depressive disorder and serum BDNF expression: a randomly double-blind, fluoxetine adjunct, placebo-controlled, pilot clinical study. 2015 , 11, 2013-21	17
148	Antidepressants. 2015 , 2052-2087	1
147	Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder. 2015 , 54, 557-64	31
146	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. 2015 , 29, 459-525	381
145	Use of a specialty clinic to teach a standardized approach to mood disorders in a family medicine residency. 2015 , 50, 17-24	1
144	Antidepressants and the adolescent brain. 2015 , 29, 545-55	29
143	Machine learning approaches for integrating clinical and imaging features in late-life depression classification and response prediction. 2015 , 30, 1056-67	83
142	Hamilton depression rating subscales to predict antidepressant treatment outcome in the early course of treatment. 2015 , 175, 199-208	5
141	Suggestibility as a predictor of response to antidepressants: A preliminary prospective trial. 2015 , 185, 8-11	8
140	Latent classes of nonresponders, rapid responders, and gradual responders in depressed outpatients receiving antidepressant medication and psychotherapy. 2015 , 32, 213-20	14

139	Allelic variation in 5-HTTLPR and the effects of citalopram on the emotional neural network. 2015 , 206, 385-92	17
138	Effects of chronic fluoxetine treatment on anxious behaviour of BALB/c mice in a 3-dimensional maze. 2015 , 18, 677-85	8
137	A neurocognitive model for understanding treatment action in depression. 2015 , 370, 20140213	42
136	Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients. 2015 , 232, 1347-56	18
135	Ketamine as a rapid antidepressant: the debate and implications. 2016 , 22, 222-233	10
134	Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. 2016 , 46, 623-35	80
133	[Unsatisfactory response: definition and involvement]. 2016 , 42, 1531-8	
132	Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--The EMC trial. 2016 , 26, 705-16	30
131	Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder. 2016 , 55, 851-859.e2	44
130	Can we at least learn to fail faster?. 2016 , 15, 243-244	1
129	Evidence-Based Selection and Use of Antidepressants in Psychiatric Practice. 2016 , 46, 659-664	
128	A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. 2016 , 6, e834	53
127	Geriatric Home-Based Medical Care. 2016 ,	2
126	[Switching and combining strategies of antidepressant medications]. 2016 , 45, 329-37	3
125	Clinical Trials of Antidepressants. 2016 ,	4
124	Palliative Care. 2016 , 251-267	2
123	Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. 2016 , 173, 174-83	116
122	Antidepressant drug action--From rapid changes on network function to network rewiring. 2016 , 64, 285-92	31

121	Resting-state brain alteration after a single dose of SSRI administration predicts 8-week remission of patients with major depressive disorder. 2017 , 47, 438-450	22
120	A model for continuous monitoring of patients with major depression in short and long term periods. 2017 , 25, 487-511	2
119	Different functioning of prefrontal cortex predicts treatment response after a selective serotonin reuptake inhibitor treatment in patients with major depression. 2017 , 214, 44-52	34
118	Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder. 2017 , 37, 555-561	6
117	Initiation of Behavioral Response to Antidepressants by Cholecystokinin Neurons of the Dentate Gyrus. 2017 , 95, 564-576.e4	31
116	Reported maladaptive decision-making in unipolar and bipolar depression and its change with treatment. 2017 , 257, 386-392	8
115	Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with Major Depressive Disorder: Systematic review and meta-analysis. 2017 , 94, 96-106	36
114	Lost in translation? The potential psychobiotic <i>Lactobacillus rhamnosus</i> (JB-1) fails to modulate stress or cognitive performance in healthy male subjects. 2017 , 61, 50-59	182
113	Randomized, double-blind, placebo-controlled study of methylphenidate for the treatment of depression in SSRI-treated cancer patients receiving palliative care. 2017 , 26, 1763-1769	8
112	Fish oil and depression: The skinny on fats. 2017 , 16, S115-S124	15
111	Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression. 2017 , 11, 48	41
110	Beyond negative valence: 2-week administration of a serotonergic antidepressant enhances both reward and effort learning signals. 2017 , 15, e2000756	22
109	A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial. 2017 , 18, 496	14
108	The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram. 2018 , 84, 152-159	12
107	Depression. 87-102	
106	Efficacy of Sertraline in Patients With Major Depressive Disorder Naive to Selective Serotonin Reuptake Inhibitors: A 10-Week Randomized, Multicenter, Placebo-Controlled, Double-Blind, Academic Clinical Trial. 2018 , 38, 454-459	2
105	The effects of six-day SSRI administration on diurnal cortisol secretion in healthy volunteers. 2018 , 235, 3415-3422	8
104	Timing of onset of lithium relapse prevention in bipolar disorder: evidence from randomised trials. 2018 , 213, 664-666	6

103	Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. 2018 , 106, 61-68	70
102	High expectancy and early response produce optimal effects in sertraline treatment for post-traumatic stress disorder. 2018 , 213, 704-708	8
101	Prenatal stress and models explaining risk for psychopathology revisited: Generic vulnerability and divergent pathways. 2018 , 30, 1041-1062	30
100	Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis. 2019 , 214, 4-10	13
99	Predictability of Nonremitting Depression After First 2 Weeks of Antidepressant Treatment: A VAST-D Trial Report. 2019 , 1, 58-67	3
98	The First Food and Drug Administration-Indicated Drug for Postpartum Depression-Brexanolone. 2019 , 76, 1001-1002	6
97	Guidelines for the diagnosis and treatment of depressive disorders in China: The second edition. 2019 , 253, 352-356	4
96	A controlled study of the efficacy and safety of tandospirone citrate combined with escitalopram in the treatment of vascular depression: A pilot randomized controlled trial at a single-center in China. 2019 , 114, 133-140	2
95	Depression in primary care: part 2-management. 2019 , 365, 1835	19
94	Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. 2019 , 29, 529-538	22
93	Plasma serotonin levels are associated with antidepressant response to SSRIs. 2019 , 250, 65-70	26
92	Cognitive neuropsychological theory: Reconciliation of psychological and biological approaches for depression. 2019 , 197, 38-51	5
91	Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders. 2019 , 36, 198-212	30
90	Symptom-specific effects of cognitive-behavioral therapy, sertraline, and their combination in a large randomized controlled trial of pediatric anxiety disorders. 2020 , 61, 492-502	6
89	Ensemble Learning for Early-Response Prediction of Antidepressant Treatment in Major Depressive Disorder. 2020 , 52, 161-171	9
88	Geriatric Pharmacology. 2020 , 102-136	
87	Peripheral microvascular serotonergic signaling is dysregulated in young adults with major depressive disorder. 2020 , 128, 100-107	4
86	Changes in antidepressant therapy should be considered early in patients with inadequate response to a first-line agent. 2021 , 55, 1033-1038	2

85	Treatment-Resistant Depression in a Real-World Setting: First Interim Analysis of Characteristics, Healthcare Resource Use, and Utility Values of the FondaMental Cohort. 2020 , 10,	6
84	A mechanistic account of serotonin's impact on mood. 2020 , 11, 2335	11
83	A Brief History of Psychopharmacology. 2020 , 1-34	
82	Drugs to Treat Depression. 2020 , 227-267	
81	A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression. 2020 , 275, 38-43	13
80	Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment. 2021 , 238, 1265-1278	21
79	Medical cannabis treatment for chronic pain: Outcomes and prediction of response. 2021 , 25, 359-374	15
78	The darkness and the light: diurnal rodent models for seasonal affective disorder. 2021 , 14,	1
77	Depression in the Emergency Department. 2021 , 89-93	
76	Serotonin modulates learning content-specific neuroplasticity of functional brain networks.	
75	Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. 2021 , 41, 172-179	1
74	The effects of KaiXinSan on depression and its association with lipid profiles: A randomized, double-blinded, placebo-controlled trial. 2021 , 83, 153467	3
73	An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress. 2021 ,	9
72	Biomarkers for Deep Brain Stimulation in Animal Models of Depression. 2021 ,	1
71	Radiation Oncology Program Directors' Attitudes Toward Twenty-Seven Discrete Palliative Care Skills. 2021 ,	0
70	Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data. 2021 , 11, 381	7
69	SSRIs modulate asymmetric learning from reward and punishment.	2
68	Serotonergic Effects on Interoception.	1

67	Analysis of print news media framing of ketamine treatment in the United States and Canada from 2000 to 2015. 2017 , 12, e0173202	8
66	Citalopram and group psychotherapy in breast cancer patients: A randomized clinical trial. 2018 , 32, 68	1
65	A new paradigm for the prediction of antidepressant treatment response. 2009 , 11, 435-46	48
64	Pharmacological approaches to the treatment of complicated grief: rationale and a brief review of the literature. 2012 , 14, 149-57	32
63	Folate Augmentation of Treatment--Evaluation for Depression (FolATED): randomised trial and economic evaluation. 2014 , 18, vii-viii, 1-159	20
62	Prognostic subgroups for citalopram response in the STAR*D trial. 2014 , 75, 738-47	50
61	A Randomized Placebo-Controlled Trial of Omega-3 and Sertraline in Depressed Patients With or at Risk for Coronary Heart Disease. 2019 , 80,	12
60	Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. 2008 , 69, 946-58	139
59	Prediction of response within the first 3 days to treatment with paroxetine for depression. 2008 , 10, 129-32	3
58	Is the Ultimate Treatment Response Predictable with Early Response in Major Depressive Episode?. 2016 , 53, 245-252	2
57	Comparison of pharmacological profiles of serotonin norepinephrine reuptake inhibitors. 2010 , 1, 10-15	1
56	Early Improvement in One Week Predicts the Treatment Response to Escitalopram in Patients with Social Anxiety Disorder: A Preliminary Study. 2016 , 14, 161-7	3
55	Unipolare Depression [Pharmakotherapie und Psychotherapie (ICD-10 F3)]. 2009 , 131-169	1
54	Attention deficit-hyperactivity disorder and early-onset bipolar disorder: two facets of one entity?. 2009 , 11, 63-72	12
53	Antidepressivos. 2011 , 219-246	
52	Antidepressants. 2012 , 1185-1198	
51	Encyclopedia of Psychopharmacology. 2013 , 1-4	
50	Developing a More Effective and More Efficient Clinical Trial Model. 2013 , 61-72	

- 49 Elaboration of the New Theory of Depression and Conclusions. **2013**, 73-80
- 48 False Assumptions: The Multidimensional Quality and its Relationships to Functioning of the Central Nervous System. **2013**, 39-52
- 47 Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (II) : Antidepressant Efficacy Compared with Placebo, Difference in Efficacy of Antidepressants, and Appropriate Time of Efficacy Judgment in Antidepressant Therapy. **2013**, 52, 372 1
- 46 Biological Treatment of Mood Disorders. 143-172
- 45 Therapie Psychischer Erkrankungen - Pages 1-91. **2014**, 1-91
- 44 [Evidence-based choice and antidepressants treatment in psychiatry]. **2015**, 115, 36-42
- 43 Therapie Psychischer Erkrankungen - Pages e1-e96. **2015**, e1-e96
- 42 Pharmacological Management of Anxiety and Depression in Older People. **2016**, 93-113
- 41 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage. **2017**, 1-111
- 40 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. **2019**, 1-119
- 39 Brief Web-Based Intervention for Depression: Randomized Controlled Trial on Behavioral Activation (Preprint).
- 38 Serotonin in the elderly. **2020**, 79-81
- 37 TCM Substances in Neuropsychopharmacotherapy. **2021**, 1-44
- 36 Risk of hospitalized depression and intentional self-harm with brand and authorized generic sertraline. **2022**, 296, 635-641
- 35 Serotonin in the elderly. **2020**, 1, 79-81
- 34 Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders. **2020**, 35, 1
- 33 Time to feel good: the therapeutic time course of antidepressants. **2007**, 4, 25-7
- 32 Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. **2009**, 10, 664-71 63

- 31 Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies. **2008**, 8, 121-32 35
- 30 Time-to-effect of fluoxetine in children with depression. **2019**, 65, 549-551
- 29 . **2019**, 65, e336-e338
- 28 Escitalopram modulates learning content-specific neuroplasticity of functional brain networks.. **2021**, 247, 118829 3
- 27 Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence".. **2022**, 82, 349 1
- 26 Cortical Thickness Predicts Response Following 2 Weeks of SSRI Regimen in First-Episode, Drug-Naïve Major Depressive Disorder: An MRI Study.. **2021**, 12, 751756
- 25 Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naïve Patients With Major Depressive Disorder.. **2022**, 16, 831278 0
- 24 Dynamic Resting-State Network Biomarkers of Antidepressant Treatment Response. **2022**, 0
- 23 Depression and Anxiety Disorders. 305-450
- 22 Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti-depressive drug on the market.. **2021**, 2
- 21 Probabilistic Reinforcement Learning and Anhedonia.. **2022**, 1 1
- 20 Protocol for the Ketamine for Postoperative Avoidance of Depressive Symptoms (K-PASS) feasibility study: A randomized clinical trial. 11, 510
- 19 A National Retrospective Study of Antidepressants Effects on Overdose and Self-Harm Among Adults Treated With Opioid Analgesics. 0
- 18 Serotonin modulates asymmetric learning from reward and punishment in healthy human volunteers. **2022**, 5, 0
- 17 Prescription of selective serotonin reuptake inhibitors in COVID-19 infection needs caution. 13, 1
- 16 Common changes in rat cortical gene expression after chronic treatment with chlorpromazine and haloperidol may be related to their antipsychotic efficacy. **2022**, 101015 0
- 15 Replication of distinct trajectories of antidepressant response to intravenous ketamine. **2023**, 321, 140-146 0
- 14 TCM Substances in Neuropsychopharmacotherapy. **2022**, 451-493 0

- 13 Efficacy and Safety of Vilazodone treatment for Major Depressive Disorder (MDD): A 3390 patients' meta-analysis of randomized controlled trials.. o
- 12 Systematic review of studies using platelet serotonin content to assess bioeffect of serotonin reuptake inhibitors at the serotonin transporter. o
- 11 Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19. 13, o
- 10 A unified model of ketamine's dissociative and psychedelic properties. 026988112211400 o
- 9 Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis. **2022**, 1, e000017 o
- 8 Early Response to Antidepressant Medications in Adults With Major Depressive Disorder. **2023**, 43, 46-54 o
- 7 Olfaction and Depression: Does the Olfactory Bulbectomized Rat Reflect a Translational Model for Depression?. o
- 6 Common roles for serotonin in rats and humans for computations underlying flexible decision-making. o
- 5 Association of Medicaid Expansion With Postpartum Depression Treatment in Arkansas. **2023**, 4, e225603 o
- 4 Rethinking the medication management of major depression. **2023**, 23, 331-363 o
- 3 Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial. **2023**, 23, o
- 2 Connecting Dots between Mitochondrial Dysfunction and Depression. **2023**, 13, 695 o
- 1 Ketamine affects homeostatic sleep regulation in the absence of the circadian sleep-regulating component in freely moving rats. **2023**, 173556 o